WELCOME
TO OUR HOMEPAGE
InflaRx is a highly innovative biotech company developing new therapeutics in the
field of inflammation. InflaRx consists of a team of internationally recognized
researchers and clinicians who have dedicated their careers to translate their
discoveries and expertise into new therapeutic concepts for clinical application.
InflaRx has set its main focus on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therpapeutics in order to prevent organ dysfunction or limit progression into organ failure. InflaRx´ lead drug candidate, IFX-1, is currently in clinical development.
| NEWS | SEPSIS "Hub" Jena | |
-Jan 2012 InflaRx announces successful conduct of its clinical phase I trial with IFX-1 -March 2011 InflaRx initiates the clinical phase I trial of its lead drug antibody IFX-1 -March 2011 InflaRx receives clinical trial authorization (CTA) for its phase I trial investigating safety and tolerability of its first-in-class monoclonal antibody IFX-1 -May 2009 InflaRx company profile on BioCentury -May 2009 InflaRx receives large scale R&D fund from the German Federal Minestry of Education and Research (BMBF) -Dec 2008 InflaRx successfully closes its 3rd financing tranche with the Affentranger Assoc. Group, Private Equity Thüringen GmbH and KFW Mittelstandsbank |
InflaRx is situated in Jena, Germany as part of the biotech cluster in the Center for Bioinstruments and holds close collaborations with the University Hospital of the Friedrich-Schiller-University in Jena where a worldwide recognized Sepsis HUB has been established with large scale federal funding. In the past 10 years, Jena has become one of the best organized clinical sites in the world to initiate and conduct clinical multicenter trials in the area of intensive care and Sepsis. | |
Pictures: Biocentive GmbH